ClinicalTrials.gg
RecruitingNCT07189936Updated Jan 22, 2026

Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS

A Phase 2 interventional study of To Measure levels of circulating monocyte/ T cell doublets at Baseline and To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment in Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS) and SARS CoV 2 Infection, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Vanderbilt University Medical Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States — 63 open to participants now, 85 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.

Planned enrollment
82nd of 156
50 · median 53
Started
2025
with 28 others
Phase 2
48 of 195
11 open now
Primary completion
2028-06
later than 67 of 84 live
Registered
178th of 195
by date
Lead sponsor
4 of 195
Vanderbilt University Medical Center

Among the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 82nd largest by planned enrollment of the 156 interventional ones that give a count, is one of 29 that started in 2025, is one of 48 in phase 2, reaches primary completion later than 67 of the 84 other live ones, and was the 178th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

63 of the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, or all of them as a file.
02

Study summary

Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID.

Long COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS) symptoms include fatigue, exercise intolerance, orthostatic intolerance, syncope, and heightened orthostatic tachycardia.

Research has found that decreased parasympathetic activity in LCPOTS increases the production of highly immunogenic neoantigens Isolevuglandins (IsoLG-adducts). IsoLG-adducts induce formation of circulating monocyte/T cell complexes(doublets) leading to the persistent and unresolved immune response that continues after the initial infection.

The purpose of the this research, is to study the effects of 2-hydroxybenzylamine (2-HOBA), an Iso-LG-adduct scavenger, its effects in immune markers and compare it with Placebo

Read the detailed description

Background:

Decreased parasympathetic activity is present in LCPOTS; this system is an important modulator of NAPDH oxidase activity because the activation of NADPH oxidase in monocytes promotes superoxide (reactive oxygen species -ROS) production.Oxidative stress occurs when ROS are generated in excess of normal antioxidants. Oxidative stress occurs when reactive oxygen species (ROS) are generated in excess of normal antioxidantsOxidative stress occurs when reactive oxygen species (ROS) are generated in excess of normal antioxidants that can cause harm by having adverse effects on T cell function. Targeting downstream damaging effects of ROS is an attractive alternative.

Rationale and Specific Aims

Reduced parasympathetic activity increases the production of highly immunogenic neoantigens, Isolevuglandins (IsoLG-adducts), through heightened activation of NADPH oxidase. Previous findings demonstrated that the cholinergic enhancer galantamine, reduces NADPH oxidase activation and that vagal stimulation reduces IsoLG-adducts in immune cells of LCPOTs patients.

Immune activation in response to viral or likely self-antigen presentation can induce formation of circulating monocyte/T cell complexes(doublets).The presence of these doublets provides powerful insights into the persistent and unresolved immune response that continues after the initial infection. The preliminary data show that: 1) LCPOTS subjects have markedly increased circulating doublets compared to controls; 2) T cells in these doublets produce higher levels of inflammatory cytokines IL-17A and IFN-ɣ than singlet T cells; and 3) inflammatory cytokines positively associate with the severity of orthostatic tachycardia in LCPOTS.

Monocytes in these doublets exhibit high levels of IsoLGs. These results support the hypothesis that LCPOTS represents a condition of unresolved immune activation due to IsoLG-adducts, which we have shown can act as neoantigens.

Study Aims Aim 1: To test the hypothesis that IsoLG-adducts directly contribute to persistent immune activation as measured by elevated monocyte/T cell doublets in LCPOTS.

For this purpose, the effect of 28-day treatment with Iso-LG-adduct scavenger, 2-hydroxybenzylamine (2-HOBA) versus placebo will be tested on circulating monocyte/ T cell doublets, and inflammatory cytokines.

Aim 2: To test the hypothesis that IsoLG-adducts directly contribute to splanchnic vasodilation, orthostatic tachycardia, and symptom burden in LCPOTS.

Aim 2 will be tested using the same experimental design as Aim 1 but will be focused on assessing changes in splanchnic venous capacitance with 2-HOBA treatment.

The proposed study will determine if IsoLG-adducts contribute to persistent immune activation, increased splanchnic venous capacitance, and orthostatic tachycardia in LCPOTS. The goal is to discover new treatment pathways for this disabling disease.

Study population: Total of 50 LCPOTS patients

Study visits: 3 in person study visits and 1 telemedicine

Study Interventions 2-HOBA: 2-hydroxybenzylamine, an IsoLGs potent scavenger.

Safety of 2-HOBA: 2-HOBA was found to be non-cytotoxic and non-mutagenic. It showed a low risk of QT prolongation. Two phase I studies on healthy subjects showed no serious side effects from 2-HOBA at doses ranging from 50 mg to 825 mg. Adverse events (AEs) reported were minor (e.g., headache, sleepiness, abdominal bloating) and were not dose-dependent.

2-HOBA is considered safe for healthy humans.

Dose: A dose of 500 mg three times daily for 28 day to study 2-HOBA for LCPOTS.

Biostatistical Considerations:

Sample size justification and study power (Aim 1). A mean percent of doublets of 5.37 and an SD of 4.28 for the LCPOTS group and a mean percent of doublets of 1.80 and an SD of 1.15 for the control group. The study is to assess for the primary comparison (2-HOBA vs. placebo). A sample size of 16 completed subjects per study arm will have 85% power to detect a 3.57 clinically meaningful difference, i.e., 5.37 versus 1.80 using a Welch t-test. Assuming a drop-out rate of 11%, we need to enroll 18 subjects to have 16 complete subjects per group. Given that subjects will be randomly assigned to two groups. The total enrollment needs to be 36 LCPOTS patients.

Sample size justification and study power (Aim 2). In a previous study, nitroglycerine produces a change from baseline in the Y-intercept of the P-V relationship of 5.7% with a standard deviation (SD) of 1.8 in healthy subjects. A clinically significant difference in the response to 2-HOBA versus placebo is assumed would be at least 35% of that produced with nitroglycerine, with conservatively slightly larger SD of 2.0. The study needs 19 patients per group to be able to reject the null hypothesis that this response difference is zero with a probability (power) of 85%. The Type I error probability associated with this test of this null hypothesis is 0.05. Assuming an attrition rate of 11%, the study needs 25 patients per treatment group. The total enrollment thus needs to be 50 LCPOTS patients.

Statistical Analyses:

The analysis population includes all randomized participants following intention-to-treat analyses.

Aim 1: For the primary comparison between 2-HOBA and placebo, a linear regression model will be used, with doublets (the primary endpoint) at the end of the 28-day treatment as the dependent variable and group indicator, baseline doublets, and other pre-specified baseline variables (age and sex) as covariates.

Aim 2: For the primary comparison between 2-HOBA versus placebo, a linear regression model will be used where splanchnic venous capacitance (SVC, primary endpoint) at the end 28-day treatment is the dependent variable and group indicator and baseline SVC and age and sex as covariates. For both aims, the null hypothesis of no group difference corresponds to the coefficient for the group indicator, which is zero. Appropriate transformation will be used on the outcome variable for the regression models when the normality assumption is violated. Other secondary endpoints will be analyzed similarly to the primary endpoint. The primary and secondary analyses will be conducted without imputing missing data. To protect privacy, subjects will receive a de-identified code. Data will be stored in a password protected, encrypted, and HIPAA compliant REDCap database.

Data and Safety Monitoring Plan:

Data and Safety Monitoring Officer (DSMO) will meet at least twice a year and review data on AEs, data quality, and study recruitment. Reports will be sent to the IRB and FDA at least yearly. Serious AEs will be reported to the FDA following guidelines using the online reporting portal.

03

Conditions studied

  • Post-Acute COVID-19 Syndrome
  • Postural Tachycardia Syndrome (POTS)
  • SARS CoV 2 Infection
  • Long COVID19

Keywords

  • Long COVID
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All participants should meet diagnostic criteria for Long COVID and POTS and as outlined below:

Long COVID (LC) is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection.

POTS: the presence of chronic symptoms lasting more than 3 months, along with orthostatic tachycardia (a HR increase over 30 bpm upon standing or exceeding 120 bpm without orthostatic hypotension) within 10 minutes upon standing or 75-degree head up tilt.

For patients aged 18 and 21, an increase of more than 40 bpm or a standing HR over 130 bpm will be required for inclusion in the study.

2 Patients need confirmation of POTS diagnosis based on orthostatic vital signs obtained prior to enrollment in the study.

SARS-CoV-2 infection 3 or more months prior identified by the follow signs:

A. Meets the clinical OR epidemiological criteria.

  1. Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia.
  2. Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Presents with acute respiratory infection with history of fever or measured fever of ≥ 38°C; and cough; with onset within the last 10 days; and who requires hospitalization); or C. Presents with no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 antigen-Rapid Diagnostic Test.

D. A person with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or E. Meeting clinical criteria AND/OR epidemiological criteria (See A). With a positive professional use or self-test, SARS-CoV-2 Antigen-Rapid Diagnostic Test.

F. Documented by health care provider in clinical note or encounter.

Exclusion criteria

Exclusion Criteria:

  1. Known active acute SARS-Cov-2 infection (4 weeks from onset)
  2. Moderate or severe patients,
  3. Known history of cardiovascular disease (atrioventricular block (AV block), myocardial infarction, angina, heart failure, pacemaker, stroke, within 6 months before enrollment),
  4. Uncontrolled hypertension (BP>140/90 despite appropriate treatment);
  5. Type 1 or type 2 diabetes mellitus;
  6. Impaired hepatic function ( or ALT greater than 1.5x the or with total ≥1.5mg/dl),
  7. Impaired renal function test (\<60 mL/min/1.73m2),
  8. Anemia ( \<10 g/dl),
  9. Pregnant or breastfeeding women,
  10. Known history of disease, use or other immunotherapies,
  11. Inability to provide .

We will also exclude individuals with known allergy sensitivity to components of the study medication, known to the study interventions, use of central acetylcholinesterase inhibitors (e.g., pyridostigmine, donezepil), aspirin allergy because salicylic acid is a metabolite of 2-HOBA; use of monoamine oxidase inhibitors (MAO-I) because of some inhibition of MAO-A is present in the anticipated therapeutic range of 2-HOBA.

-

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Placebo comparator
    Levels of circulating monocyte/ T cell doublets, and inflammatory cytokines in 2 HoBA Vs Placebo

    to test the effect of 28-day treatment with Iso-LG-adduct scavenger, 2-hydroxybenzylamine (2-HOBA) versus placebo on circulating monocyte/ T cell doublets (CD14+CD3+) , and inflammatory cytokines

    Drug: To Measure levels of circulating monocyte/ T cell doublets at Baseline · Drug: To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment · Drug: To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment

  • Placebo comparator
    Effect of 2HOBA on Splanchnic venous capacitance and compare with placebo group on POTS patients

    To test the hypothesis that IsoLG-adducts directly contribute to splanchnic vasodilation, by assessing changes in splanchnic venous capacitance with 2-HOBA treatment at head up Tilt

    Diagnostic Test: To Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA · Diagnostic Test: To Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo

  • Active comparator
    Effect of 2HOBA on Orthostatic Tachycardia compare with placebo group during 30 minutes head up tilt

    To test that IsoLG-adducts directly effect Orthostatic tachycardia in LCPOTS, during 30-minute head-up tilt.

    Diagnostic Test: To Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA · Diagnostic Test: To Measure Orthostatic Tachycardia after 28 days of Treatment with Placebo

Interventions

  • DrugTo Measure levels of circulating monocyte/ T cell doublets at Baseline

    To determine the levels of circulating monocyte/ T cell doublets on all the LCPOTS subjects

  • DrugTo measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment

    Subjects will be randomized 1:1 to 2-HOBA or matching placebo. The levels of circulating monocyte/ T cell doublets (immune burden) after 28 days of 2 HOBA treatment

  • DrugTo measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment

    The levels of circulating monocyte/ T cell doublets (immune burden) after 28 days of 2 HOBA treatment and compare it to the placebo arms

  • Diagnostic testTo Measure Splanchnic venous capacitance after 28 days of Treatment with 2HOBA

    We will Measure changes in Splanchnic venous capacitance after 28 days of Treatment with 2HOBA and compare it with baseline during 30 Mins head up tilt . All the LCPOTS subjects will be randomized 1:1 to 2-HOBA or matching placebo

  • Diagnostic testTo Measure Splanchnic venous capacitance after 28 days of Treatment with Placebo

    We will Measure changes in splanchnic venous capacitance during 30 mins head up tilt ,after 28 days of Treatment with Placebo, we will compare it to the subjects who received 2 HOBA for 28 days

  • Diagnostic testTo Measure Orthostatic Tachycardia after 28 days of Treatment with 2HOBA

    To Measure changes in Orthostatic Tachycardia after 28 days of Treatment with 2HOBA at 30 minutes of head up Tilt

  • Diagnostic testTo Measure Orthostatic Tachycardia after 28 days of Treatment with Placebo

    To Measure changes in Orthostatic Tachycardia after 28 days of Treatment with Placebo at 30 minutes of head up Tilt and compare it with the subjects who received 28 days of 2HOBA

06

What researchers measure

Primary outcomes

  1. Effect IsoLG-adducts (2-HOBA) measured by levels of monocyte/T cell doublets in LCPOTS.

    The effect of 28-day treatment with Iso-LG-adduct scavenger, 2-hydroxybenzylamine (2-HOBA) versus placebo on circulating monocyte/ T cell doublets, and inflammatory cytokines and compare it to the placebo

    Time frame: Baseline (Day 0) to after 28 days of treatment

  2. Changes in Splanchnic venous capacitance before and after 28 days of treatment

    Changes in Splanchnic venous capacitance at 30 mins Head up tilt, before and after 28 days of treatment and compare it with 2-HOBA group with placebo group

    Time frame: Day 0- Day 28 days

Secondary outcomes

  1. Measure the effects of 2- HOBA on Orthostatic Tachycardia at HUT

    To see the effects of IsoLG-adducts (2-HOBA) on Orthostatic Tachycardia in LCPOTS subjects at 30 mins Head up Tilt (HUT) and compare it with Placebo group

    Time frame: Baseline (Day0) to after 28 days of study medication

07

Study locations

1 of 1 sites recruiting
  • Cyndya Shibao
    Nashville, Tennessee 37027, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2028, 30 months after the start.

Of 46 non-industry phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 24. This study's planned 30 months is above that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Sep 24, 2025
StartActual
Dec 18, 2025
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2029
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07189936
Collaborators
American Heart Association
Responsible party
Cyndya Shibao, MD (Professor, Vanderbilt University Medical Center) — Principal investigator
First posted
Sep 24, 2025
Start date
Dec 18, 2025
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Jan 22, 2026

Study contacts

Marwa Mohamed, PhD
Contact
marwa.mohamed@vumc.org
6159702384
Cyndya Shibao, MD
Contact
Cyndya.shibao@vumc.org
(615)936-4584
Cyndya Shibao, M.D
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion